A Single-Arm Phase II Clinical Trial of Cabozantinib (XL184) in Patients With Previously Treated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases With and Without C Met Amplification
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Jan 2016 Planned End Date changed from 1 Dec 2027 to 1 Jun 2028 as reported by ClinicalTrials.gov record.
- 13 Jan 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018 as reported by ClinicalTrials.gov record.
- 13 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.